卡铂加顺铂治疗晚期非小细胞肺癌的疗效观察

THERAPEUTIC RESULT OF PHASE II CLINICAL TRIAL OF CISPLATIN PLUS CARBOPLATIN THERAPY IN NON-SMALL CELL LUNG CANCER(NSCLC)

全组１９例经病理学证实的晚期非小细胞肺癌。应用卡铂３００ｍｇ／ｍ２第１天静脉输入，顺铂２０ｍｇ／ｍ２第１～３天静脉输入，每３周重复一次。１９例均可评定疗效与毒性。８例（４２．１％）获部分缓解，无完全缓解病例。其中未接受过化疗的１５例，７例（４６．７％）获部分缓解。毒副反应主要为骨髓抑制，消化道反应等。

A phase II pilot study of carboplatin 300mg/m2 followed by cisplatin60mg/m2 was initiated in 19 patients with NSCLC. Interim analysis showed that 8 patentshave had at least a partial response to cisplatin/carboplatin, with a response rate of 42.1%The response rate in previously untreated patients was 46. 7%,while in previously treatedpatients was 25%. No serio us adverse effects were oberved.Futher studies with the cis-platin/carboplatin combination in NSCIC are warranted.